SpecialtiesQuestion

For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?

In patients with resected stage II-III NSCLC, who completed adjuvant carboplatin and pemetrexed and are PD-L1 high, which immunotherapy would you offer?

Is there evidence supporting the role of SBRT in the management of oligometastatic stage IV NSCLC?

Would you give consolidation durvalumab to a patient who underwent chemoradiation for his stage III NSCLC and is being started on antifibrotic therapy by pulmonology for his ILD?

In ES-SCLC presenting with limited asymptomatic brain metastases and treated upfront with systemic therapy alone (carbo/etop/atezo), how would you approach the brain if MRI shows PR after a few cycles?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.